Dimerix Limited (DXB:ASX)

28.0¢

right-arrow Created with Sketch. 0 (0%)
MCAP $69.57M
Last trade 16.10pm 17/09/2021 20mins delayed

Latest Announcements

15/09/2021DXBDimerix Limited
03/09/2021DXBDimerix Limited
25/08/2021 Price SensitivePSDXBDimerix Limited
24/08/2021DXBDimerix Limited
24/08/2021DXBDimerix Limited
24/08/2021 Price SensitivePSDXBDimerix Limited
24/08/2021DXBDimerix Limited
24/08/2021DXBDimerix Limited

Company Overview

Dimerix Limited is an Australia-based biopharmaceutical company. The Company is engaged in the development of new therapies in areas with unmet medical need. The Company is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.

DXB in the news

Dimerix (DXB) kicks off a Phase 3 clinical study in patients with…
Dimerix (DXB) receives firm commitments to undertake a two-phase placement to raise…
Dimerix (DXB) moves a step closer towards phase three clinical trials for…

Search Previous Announcements